



RESTRICTION ELECTION FACSIMILE TRANSMISSION

DATE: 25 June 2001
FROM/ATTORNEY: Dean Nakamura
FIRM: Roylance et al.
PAGES, INCLUDING COVERSHEET: 61
PHONE NUMBER: 202.530.7362

FAX RECEIVED
JUN 6 2001
GROUP 1600

TO EXAMINER: N. Davis
ART UNIT: 1643
SERIAL NUMBER: 09/610,891
FAX/TELECOPIER NUMBER: (703) 308-4315

PLEASE NOTE: THIS FACSIMILE NUMBER IS TO BE USED ONLY
FOR RESPONSES TO RESTRICTIONS.

COMMENTS:

IF YOU HAVE NOT RECEIVED ALL THE PAGES OF THIS TRANSMISSION, PLEASE CONTACT THE ATTORNEY AT THE
TELEPHONE NUMBER LISTED ABOVE.

IN COMPLIANCE WITH 109 LOG 30, THE FILING DATE ACCORDED EACH OFFICIAL FAX TRANSMISSION WILL BE
DETERMINED BY THE FAX MACHINE DATE STAMP FOUND ON THE LAST PAGE OF THE TRANSMISSION, UNLESS THAT
DATE IS A SATURDAY, SUNDAY, OR FEDERAL HOLIDAY WITHIN THE DISTRICT OF COLUMBIA, IN WHICH CASE THE
OFFICIAL DATE OF RECEIPT WILL BE THE NEXT BUSINESS DAY.

THE DOCUMENT(S) ACCOMPANYING THIS FACSIMILE TRANSMISSION CONTAIN(S) INFORMATION FROM THE UNITED
STATES PATENT AND TRADEMARK OFFICE WHICH IS CONFIDENTIAL AND/OR LEGALLY PRIVILEGED. THIS
INFORMATION IS FOR THE USE OF THE INDIVIDUAL OR FIRM NAMED ON THIS SHEET. IF YOU ARE NOT THE INTENDED
RECIPIENT, YOU ARE HEREBY NOTIFIED THAT ANY DISCLOSURE, COPYING, DISTRIBUTION, OR THE TAKING OF ANY
ACTION IN RELIANCE ON THE CONTENTS OF THIS INFORMATION IS STRICTLY PROHIBITED. THE DOCUMENTS SHOULD
BE RETURNED TO THE PATENT AND TRADEMARK OFFICE IMMEDIATELY. IF THIS FACSIMILE IS RECEIVED IN ERROR,
PLEASE NOTIFY THE ATTORNEY LISTED HEREON IMMEDIATELY.

6A
7/12/01
PATENT

40567

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

James McArthur et al.

Serial No.: 09/610,891

Filed: 6 July 2001

For: NOVEL CANCER-ASSOCIATED
ANTIGENS AND METHODS OF THEIR
IDENTIFICATION AND USE

Group Art Unit 1643

Examiner: Davis

FAX RECEIVED

JUN 26 2001

GROUP 1600

PRELIMINARY AMENDMENTAssistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Prior to prosecution on the merits, kindly amend the application as follows:

IN THE CLAIMS:

Kindly cancel claims 1-22 without prejudice to prosecution in divisional applications.

Kindly add the following new claims:

--23. A vaccine comprising a nucleic acid encoding a tumor-associated antigen,
wherein said tumor-associated antigen alone does not stimulate a humoral response, and said

A1